This inventor holds 1 USPTO granted patent. Top assignees: Shanghai Synergy Pharmaceutical Sciences, Ltd., Zhejiang Huahai Pharmaceutical Co., Ltd.. Active years: 2026.
Company Filing History:
1 out of 3 
1 out of 2 Years Active: 2026
Title: The Innovative Contributions of Liangze Xia
Introduction
Liangze Xia is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of medicine through his innovative research and development of pharmaceutical compounds. His work focuses on creating effective treatments for diseases mediated by Bruton's tyrosine kinase.
Latest Patents
Liangze Xia holds a patent for "Substituted cyclopenta[4,5]pyrrolo[1,2-a]pyrazines as Bruton's tyrosine kinase inhibitors." This patent describes a compound of formula (I) that serves as a Bruton's tyrosine kinase inhibitor. The compound is particularly relevant for preventing and treating diseases related to Bruton's tyrosine kinase mediation, including autoimmune diseases, cancer, and inflammatory diseases. Experimental research has demonstrated that this compound exhibits high selectivity towards the Bruton's tyrosine kinase target and shows promising medicinal effects in in vivo animal experiments.
Career Highlights
Throughout his career, Liangze Xia has worked with notable companies in the pharmaceutical industry, including Shanghai Synergy Pharmaceutical Sciences, Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Liangze Xia has collaborated with talented individuals in his field, including Xin Xu and Jia Chen. These collaborations have further enhanced his research and development efforts.
Conclusion
Liangze Xia's innovative work in developing Bruton's tyrosine kinase inhibitors showcases his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of various diseases.